S. Frequin

发表

Correlating MRI and clinical disease activity in multiple sclerosis

H. Tobi, F. Barkhof, C. Polman, 1995, Neurology.

Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal study

J. J. Van der Klink, H. Middelkoop, S. Frequin, 2019, Neurological Sciences.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

D. Arnold, S. Muley, P. Vermersch, 2018, The Lancet Neurology.

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS

F. Barkhof, B. Uitdehaag, S. Frequin, 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

Sensory axonopathy in hereditary distal spinal muscular atrophy

F. Gabreëls, E. Joosten, S. Frequin, 1991, Clinical Neurology and Neurosurgery.

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.

Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.

F. Barkhof, J. Valk, J. Nauta, 1992, AJR. American journal of roentgenology.

Adverse Events of Interferon Beta-1a: A Prospective Multi-Centre International ICH-GCP-Based CRO-Supported External Validation Study in Daily Practice

G. Borm, W. Linssen, S. Frequin, 2011, PloS one.

Subacute Combined Spinal Cord Degeneration by Recreational Laughing Gas (N2O) Use

S. Frequin, Marthe R Onrust, 2019, Journal of central nervous system disease.

The effects of high-dose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis

F. Barkhof, O. Hommes, S. Frequin, 1992, Journal of Neuroimmunology.

Follow‐up study of MS patients treated with high‐dose intravenous methylprednisolone

F. Barkhof, G. Borm, S. Frequin, 1994, Acta neurologica Scandinavica.

High-dose intravenous methylprednisolone treatment in multiple sclerosis: a clinical study

S. Frequin, 1993 .

CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high‐dose intravenous methylprednisolone

F. Barkhof, G. Borm, O. Hommes, 1992, Acta neurologica Scandinavica.

Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands

B. Uitdehaag, J. V. Wingerden, S. Frequin, 2018, Journal of medical economics.

MRI pattern in asymptomatic natalizumab-associated PML

F. Barkhof, M. Steenwijk, N. Richert, 2014, Journal of Neurology, Neurosurgery & Psychiatry.

Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis

F. Barkhof, C. Polman, J. Valk, 1994, Neurology.

Patterns of Brain Magnetic Resonance Abnormalities on T2-Weighted Spin Echo Images in Clinical Subgroups of Multiple Sclerosis: A Large Cross-Sectional Study

Frederik Barkhof, Alan J. Thompson, Chris Polman, 1998, European Neurology.

A correlative triad of gadolinium‐DTPA MRI, EDSS, and CSF‐MBP in relapsing multiple sclerosis patients treated with high‐dose intravenous methylprednisolone

F. Barkhof, J. Valk, O. Hommes, 1992, Neurology.

Daily negative interactions and mood among patients and partners dealing with multiple sclerosis (MS): the moderating effects of emotional support.

J. Bensing, J. Hox, S. Frequin, 2007, Social science & medicine.

Self-reported work productivity in people with multiple sclerosis and its association with mental and physical health

H. Middelkoop, S. Frequin, E. Arnoldus, 2021, Disability and rehabilitation.

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis

S. Frequin, P. J. van der Wees, S. Frequin, 2020, Multiple sclerosis international.

Effects of immunotherapeutic strategies on cerebrospinal fluid parameters in multiple sclerosis

O. Hommes, S. Frequin, K. Lamers, 1996 .

T‐cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high‐dose intravenous methylprednisolne

F. Barkhof, G. Borm, O. Hommes, 1993, Acta neurologica Scandinavica.

Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis

F. Barkhof, J. Valk, J. Nauta, 1994, Neuroradiology.

A Dutch validation study of the Multiple Sclerosis Work Difficulties Questionnaire in relapsing remitting multiple sclerosis

H. Middelkoop, S. Frequin, P. Jongen, 2019, Disability and rehabilitation.

Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients.

B. Uitdehaag, S. Frequin, M. Wattjes, 2021, Multiple sclerosis and related disorders.

Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone

F. Barkhof, O. Hommes, S. Frequin, 1993, Journal of Neurology.

Recurrent Prolonged Coma Due to Basilar Artery Migraine. A Case Report.

O. Hommes, S. Frequin, J. Pasman, 1991, Headache.

Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing–remitting multiple sclerosis in The Netherlands

S. Frequin, M. Heisen, M. Groot, 2012, Journal of medical economics.

A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.

S. Frequin, B. V. van Oosten, E. Hoogervorst, 2020, Multiple sclerosis and related disorders.

Cerebrospinal Venous Outflow in Multiple Sclerosis Patients versus Fatigue and/or Depression

S. Frequin, S. Tromp, Marloes H. J. Hagens, 2014, Interventional Neurology.